For Healthcare Providers

For Healthcare Providers


In order to assess, monitor and optimally treat noninfectious anterior uveitis, it is crucial to have accurate, consistent and conventional diagnosis of the main disease’s sign: the anterior chamber cells (ACCs).

Tarsier Pharma, in collaboration with Prof. de Smet, Prof. Cunningham, Dr. Neumann, and Dr. Kramer, have developed the Tarsier Grading Image Scale (GIS) to improve  ACC grading by slit lamp bio-microscopy. The Tarsier GIS is a visual analog scale that graphically represents a high-power field slit beam through the anterior chamber, from the cornea to the lens surface, to evaluate an anterior uveitic flare-up.

Cells were represented as white dots, dimensioned to represent lymphocytes, and distributed throughout the anterior chamber in an inhomogeneous fashion. The reference images were set at the upper limit of each grade.


A scientific article named Tarsier Anterior Chamber Cell Grading: Improving the SUN Grading Scheme with a Visual Analog Scale, about this new imaging method of cell count, was published in July 2021 in the journal OCULAR IMMUNOLOGY AND INFLAMMATION (click here to read the Open Access full article).  The new GIS ACC scheme reduced interobserver variability, and improved the correct grading of cells. 

Tarsier is proud to support this work and contribute to our community.


As a result of uveitis alone being a rare ocular disease, the familiarity with one of its main and most devastating complications, uveitic glaucoma, is low; even among the general Ophthalmology community and stakeholders. Consequently, it is important to shed some light about its unique complexity, worse prognosis, and great challenges in treatment“, Dr. Stephen Foster.

As part of our mission at Tarsier to raise awareness to uveitic glaucoma among the public and general Ophthalmology Community, we are happy to have launched a dedicated website about the disease, at:

Scroll to Top